Role of Breast Cancer Resistance Protein in the Bioavailability and Fetal Penetration of Topotecan
Johan W. Jonker,
Johan W. Smit,
Remco F. Brinkhuis,
Marc Maliepaard,
Jos H. Beijnen,
Jan H. M. Schellens,
Alfred H. Schinkel
Affiliations of authors: J. W. Jonker, J. W. Smit, R. F. Brinkhuis, M. Maliepaard, A. H. Schinkel (Division of Experimental Therapy), J. H. M. Schellens (Divisions of Experimental Therapy and Medical Oncology), The Netherlands Cancer Institute, Amsterdam; J. H. Beijnen, Department of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands.
Correspondence to: Alfred H. Schinkel, Ph.D., Division of Experimental Therapy, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands (e-mail: alfred{at}nki.nl).
 |
ABSTRACT
|
---|
Background and Methods: Breast cancer resistance protein (BCRP/MXR/ABCP) is a multidrug-resistance protein that is a member of the adenosine triphosphate-binding cassette family of drug transporters. BCRP can render tumor cells resistant to the anticancer drugs topotecan, mitoxantrone, doxorubicin, and daunorubicin. To investigate the physiologic role of BCRP, we used polarized mammalian cell lines to determine the direction of BCRP drug transport. We also used the BCRP inhibitor GF120918 to assess the role of BCRP in protecting mice against xenobiotic drugs. Bcrp1, the murine homologue of BCRP, was expressed in the polarized mammalian cell lines LLC-PK1 and MDCK-II, and the direction of Bcrp1-mediated transport of topotecan and mitoxantrone was determined. To avoid the confounding drug transport provided by P-glycoprotein (P-gp), the roles of Bcrp1 in the bioavailability of topotecan and the effect of GF120918 were studied in both wild-type and P-gp-deficient mice and their fetuses. Results: Bcrp1 mediated apically directed transport of drugs in polarized cell lines. When both topotecan and GF120918 were administered orally, the bioavailability (i.e., the extent to which a drug becomes available to a target tissue after administration) of topotecan in plasma was dramatically increased in P-gp-deficient mice (greater than sixfold) and wild-type mice (greater than ninefold), compared with the control (i.e., vehicle-treated) mice. Furthermore, treatment with GF120918 decreased plasma clearance and hepatobiliary excretion of topotecan and increased (re-)uptake by the small intestine. In pregnant GF120918-treated, P-gp-deficient mice, relative fetal penetration of topotecan was twofold higher than that in pregnant vehicle-treated mice, suggesting a function for BCRP in the maternalfetal barrier of the placenta. Conclusions: Bcrp1 mediates apically directed drug transport, appears to reduce drug bioavailability, and protects fetuses against drugs. We propose that strategic application of BCRP inhibitors may thus lead to more effective oral chemotherapy with topotecan or other BCRP substrate drugs.
 |
INTRODUCTION
|
---|
After a period of treatment with a single cytotoxic drug, cancer cells can become resistant to multiple drugs, a phenomenon known as multidrug resistance. Several mechanisms of multidrug resistance have been identified, including the overexpression of P-glycoprotein (P-gp) and MRP1, which are members of the adenosine triphosphate-binding cassette (ABC) superfamily of transport proteins that are situated in the plasma membrane and can actively transport drugs out of the cell (13). Recently, breast cancer resistance protein (BCRP) (also known as mitoxantrone resistance protein [MXR] and placenta-specific ABC transporter [ABCP]), a new member of this superfamily involved in multidrug resistance, was identified in an MCF-7 breast cancer cell subline that was selected for resistance to doxorubicin. This BCRP-overexpressing cell line was markedly cross-resistant to mitoxantrone and daunorubicin (4,5). Subsequently, several other groups (68) have shown overexpression of BCRP or its murine homologue, Bcrp1, in cell lines selected for resistance to the anticancer agents mitoxantrone, doxorubicin, and topotecan. BCRP-mediated drug resistance could be effectively reversed by GF120918 (a P-gp inhibitor) in human (9) and murine (7) cell lines.
In this study, we investigate the direction of BCRP-mediated drug transport in various polarized cell lines and determine the role of BCRP in protecting mice against xenobiotic drugs (10), by using the efficient BCRP inhibitor GF120918.
 |
MATERIALS AND METHODS
|
---|
Animals
The mice were housed and handled according to institutional guidelines and Dutch laws. For all experiments, the animals used were male mdr1a/1b(-/-) or wild-type mice of a 99% FVB genetic background; they were 914 weeks of age. The mice were kept in a temperature-controlled environment with a 12-hour light12-hour dark cycle and were given a standard diet (AM-II; Hope Farms, Woerden, The Netherlands) and acidified water ad libitum.
Reagents
Topotecan (Hycamtin®) and [14C]topotecan (56 Ci/mol) were from SmithKline Beecham Pharmaceuticals (King of Prussia, PA). GF120918 was from Glaxo Wellcome (Research Triangle Park, NC). Ketamine (Ketalar®) was from Parke-Davis (Hoofddorp, The Netherlands). Xylazine was from Sigma Chemical Co. (St. Louis, MO). Methoxyflurane (Metofane®) was from Mallinckrodt Veterinary, Inc. (Mundelein, IL). All other compounds used were reagent grade.
Drug Preparation, Administration, and Analysis
GF120918 was suspended at 5 mg/mL in a mixture of hydroxypropyl methylcellulose (10 g/L)/2% (vol/vol) Tween 80/H2O (0.5 : 1 : 98.5 [vol/vol/vol] for oral administration). Animals, lightly anesthetized with methoxyflurane, were administered GF120918 (50 mg/kg; 10 µL of drug solution/g body weight) or a corresponding amount of vehicle by gavage into the stomach. Topotecan (0.2 mg/mL) (freshly prepared in 5% [wt/vol] D-glucose; 5 µL/g body weight) was administered orally at a dose of 1.0 mg/kg body weight. For intravenous administration, topotecan or, where indicated, [14C]topotecan at 5 µL of drug solution/g body weight was injected into the tail vein of mice lightly anesthetized with methoxyflurane.
Animals were killed by cardiac puncture or axillary bleeding after being anesthetized with methoxyflurane, and their blood was collected. Heparinized plasma was mixed with three volumes of ice-cold methanol (-20 °C). Their organs were removed and subsequently homogenized in 4% (wt/vol) bovine serum albumin. Where applicable, the intestinal content was separated from the intestinal tissue before homogenization. Radioactivity in homogenates was determined as described previously (11). Because topotecan is hardly metabolized in vivo, the amounts of 14C reflect total unchanged levels of topotecan (12). The total topotecan levels (lactone plus carboxylate form) in plasma were determined by high-pressure liquid chromatography as described earlier (13). The area under the plasma concentrationtime curve (AUC) was calculated (from 0 to 4 hours for oral administration and from 1 minute to 4 hours for intravenous administration) by use of the linear trapezoidal rule. Plasma bioavailability (i.e., the extent to which a drug becomes available in plasma after administration) of administered drug was determined as the ratio of the AUC after oral and intravenous administrations. For gallbladder cannulation experiments, mice were anesthetized and cannulated as described previously (14). Anesthetics, a combination of ketamine (100 mg/kg) and xylazine (6.7 mg/kg), were injected intraperitoneally into the mice at 2.33 µL/g body weight.
Ribonuclease Protection Analysis
Total RNA was isolated from mouse tissues by use of the TRIzol® reagent (Life Technologies, Inc. [GIBCO BRL], Rockville, MD), according to the manufacturer's instructions. Ribonuclease (RNase) protection assays were performed, as described previously (15), with 10 µg of total RNA per sample. A mouse probe for bcrp1 was made by cloning a 405-nucleotide (nt) polymerase chain reaction fragment (positions 15541959 relative to the translation start) into the pGEM-T vector (Promega Corp., Madison, WI). After the vector was linearized with restriction endonuclease EcoRI, a 280-nt antisense RNA probe was generated by transcription with SP6 RNA polymerase, yielding a protected probe fragment of 205 nt.
Expression of Full-Length Mouse bcrp1 Complementary DNA in LLC-PK1 and MDCK-II Cells
The full-length mouse bcrp1 complementary DNA (cDNA) (7) was excised from pBluescript KS with SmaI and NotI and was cloned into the LZRS-MS-IRES-GFP expression vector between the SnaBI and NotI sites (16). The resulting vector was a monocistronic construct containing bcrp1 followed by sequences for an internal ribosome entry site and the enhanced green fluorescent protein. This construct was transfected to the amphotropic Phoenix producer cell line (17) by use of the calcium phosphate precipitation method. Viral supernatants from these transfected cells were used to transduce LLC-PK1 or MDCK-II cells. Transduced clones were selected first for expression of the enhanced green fluorescent protein and then for the reduced accumulation of mitoxantrone by flow cytometry. The expression of bcrp1 cDNA in selected clones was determined by northern blot analysis.
Transport Assay
Transport assays were carried out as described earlier (14), with minor modifications. M199 medium containing L-glutamine (2 mM), penicillin (100 IU/mL), streptomycin (100 µg/mL), and fetal calf serum (10%) was used throughout. Cells were seeded on microporous polycarbonate membrane filters (3.0-µm pore size, 24.5-mm diameter, TranswellTM 3414, Costar®) at a density of 2 x 106 cells/well. The cells were grown for 4 days in M199 medium with one change of medium. Ninety minutes before the start of the experiment, medium on both the apical and the basal sides of the monolayer was replaced with 2 mL of Optimem (Life Technologies Ltd., Paisley, Scotland) containing L-glutamine (2 mM), penicillin (100 IU/mL), and streptomycin (100 µg/mL) without fetal calf serum, at pH 6.5 (adjusted with HCl). The experiment was started by replacing the medium on either the apical or the basal side of the cell layer with 2 mL of Optimem (pH 6.5) containing 10 µM [14C]topotecan (7 Ci/mol) and 192 nM [3H]inulin (0.8 Ci/mmol). The cells were incubated at 37 °C in 5% CO2-95% air. After 0.5, 2, 4, 6, and 24 hours, 50 µL was taken from each compartment, and the radioactivity in each aliquot was measured. Any radioactivity crossing the monolayer and appearing in the opposite compartment was noted as the fraction of total radioactivity added at the beginning of the experiment. The tightness of the monolayer was measured by monitoring the paracellular flux of [3H]inulin to the opposite compartment. This flux was always lower than 1% of the total radioactivity per hour.
Statistical Analysis
The two-sided unpaired Student's t test was used throughout to assess the statistical significance of difference between the two sets of data. Results are presented as the means ± standard deviation. Differences were considered to be statistically significant when P<.05.
 |
RESULTS
|
---|
Polarized Transport of [14C]Topotecan by Mouse Bcrp1 in Epithelial Cell Lines
To determine the direction of Bcrp1-mediated drug transport in polarized epithelia, we transduced the pig kidney cell line LLC-PK1 with a retroviral expression vector containing mouse bcrp1 cDNA. By northern blot analysis, expression of bcrp1 cDNA in two independent transductants (L-Bcrp1.1 and L-Bcrp-1.2) was 25%50% of that found in D320 cells, a doxorubicin-selected cell line that highly overexpresses bcrp1 [(7); data not shown]. The parental and transduced cell lines were grown to confluent polarized monolayers on porous membrane filters, and vectorial transport of [14C]topotecan (10 µM) across the monolayers was determined. Background transport of topotecan by the endogenous pig P-gp (18) present in the LLC-PK1-derived lines was abolished by the addition of the P-gp inhibitor PSC 833 (10 µM). This compound hardly affects Bcrp1-mediated drug transport (data not shown). Although topotecan was translocated equally well in both apical and basolateral directions in the parental line LLC-PK1, in the bcrp1-transduced lines, it was translocated more in the apical direction and less in the basolateral direction (Fig. 1
, a and b; data for L-Bcrp1.2 [not shown] were similar to those for L-Bcrp1.1). When the Bcrp1/P-gp inhibitor GF120918 (7,9) was used, polarized topotecan transport was abolished in parental and bcrp1-transduced lines, resulting in equal levels of (passive) translocation of topotecan in both directions (Fig. 1
, c and d). Similar results were obtained for [14C]topotecan and [3H]mitoxantrone when mouse bcrp1 was expressed in the polarized canine kidney cell line MDCK-II (data not shown). Thus, Bcrp1-mediated drug transport is apically directed in various polarized cells, which suggests that Bcrp1 is located apically in polarized epithelia, and can be effectively inhibited by GF120918.

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 1. Transepithelial transport of [14C]topotecan (10 µM) in LLC-PK1 (a and c) and L-Bcrp1.1 (a representative clone) (b and d) monolayers. The experiment was started with the addition of [14C]topotecan to one compartment (basal or apical) of the culture dish. After 0.5, 2, 4, and 6 hours, the percentage of radioactivity appearing in the opposite compartment was measured and plotted. The P-glycoprotein (P-gp) inhibitor PSC 833 (a and b) or the breast cancer resistance protein (BCRP)/P-gp inhibitor GF120918 (c and d) was present as indicated. Results are the means; the error bars indicate the standard deviations (n = 3). Transport from the apical to the basal sides and from the basal to the apical sides (at 6 hours) was only significantly different for L-Bcrp1.1 cells treated with 10 µM PSC 833 (P = .002; two-sided Student's t test).
|
|
Expression of bcrp1 Messenger RNA in Mouse Tissues
P-gp mediates apically directed drug transport in polarized cultured cells and the elimination of drugs by organs such as liver and intestine. P-gp also reduces the uptake of drugs from the intestine and prevents the accumulation of drugs in certain critical tissues and the fetus (10,1921). To assess a possible pharmacologic role of Bcrp1, we first determined the tissue distribution of mouse bcrp1 by using RNase protection assays. Fig. 2
, a, shows that mouse bcrp1 is highly expressed in kidney and expressed more moderately in liver, colon, heart, spleen, and placenta. The moderate levels of bcrp1 expression in the mouse placenta contrast with the very high levels of BCRP expression previously observed in human placenta (4,22).

View larger version (59K):
[in this window]
[in a new window]
|
Fig. 2. Expression of the murine breast cancer resistance protein (bcrp1) messenger RNA in mouse tissues. Ribonuclease protection analysis was performed with 10 µg of total RNA/sample. a) bcrp1 expression in mdr1a/1b(-/-) mouse tissues: colon (lane 1), cecum (lane 2), heart (lane 3), lung (lane 4), skeletal muscle (lane 5), thymus (lane 6), stomach (lane 7), epididymis (lane 8), brain (lane 9), liver (lane 10), kidney (lane 11), spleen (lane 12), placenta (lane 13), and uterus (lane 14). b) Comparison of bcrp1 expression between wild-type (wt) and mdr1a/1b(-/-) (ko) mice: wt brain (lane 15), ko brain (lane 16), wt liver (lane 17), ko liver (lane 18), wt kidney (lane 19), ko kidney (lane 20), wt spleen (lane 21), ko spleen (lane 22), wt small intestine (lane 23), and ko small intestine (lane 24). Positions of bcrp1- and Gapdh (i.e., glyceraldehyde-3-phosphate dehydrogenase)-protected RNA fragments are indicated. The Gapdh expression differs between tissues and is used to compare amounts of RNA from the same tissues from mice with different genotypes.
|
|
Effect of GF120918-Mediated Inhibition of Bcrp1 on the Pharmacokinetics of Topotecan in Mice
We studied the pharmacologic role of Bcrp1 in vivo in liver, intestine, kidney, and placenta by analyzing the effects of the Bcrp1 inhibitor GF120918, which is well tolerated by both mice and humans [(23); unpublished data], on the pharmacokinetics of topotecan. Because GF120918 inhibits both P-gp and Bcrp1, we used P-gp-deficient mdr1a/1b(-/-) mice (10) to exclude any confounding effects of P-gp inhibition. Comparison of the expression of bcrp1 in several organs between wild-type and mdr1a/1b(-/-) mice established that expression of bcrp1 was not increased by the loss of P-gp (Fig. 2
, b). To study topotecan bioavailability, we administered GF120918 or vehicle orally to mdr1a/1b(-/-) mice 15 minutes before oral or intravenous administration of topotecan, and we determined the plasma concentration of topotecan as a function of time (Fig. 3
, a and c). In GF120918-treated animals, the bioavailability of topotecan given orally, as measured by the AUC, was more than sixfold higher than that in vehicle-treated animals (596 ± 62 versus 96 ± 18 hours mg/L; P<.001; Fig. 3
, a). In GF120918-treated animals, the bioavailability of topotecan given intravenously increased about twofold (406 ± 25 versus 200 ± 29 hours mg/L; P<.001; Fig. 3
, c). Taking the bioavailability of intravenously administered topotecan in vehicle-treated mice as 100%, the bioavailability of topotecan administered orally was 48% ± 9% in vehicle-treated mice and 299% ± 31% in GF120918-treated mice. Thus, Bcrp1 appears to be a major determinant for the bioavailability of topotecan that is administered orally.

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 3. Plasma topotecan concentration versus time curves and biliary excretion of topotecan in mice treated with GF120918 or vehicle. Mdr1a/1b(-/-) (a) or wild-type (b) mice were given an oral dose of GF120918 (50 mg/kg) or vehicle 15 minutes before an oral dose of topotecan (1 mg/kg). Plasma levels of unchanged topotecan were determined by high-pressure liquid chromatography at 15, 30, 60, 120, and 240 minutes. Results are the means ± standard deviation (n 3). c) Plasma topotecan concentration versus time curves for intravenously administered topotecan in mdr1a/1b(-/-) mice treated with GF120918 or vehicle. Mdr1a/1b mice received an oral dose of GF120918 (50 mg/kg) or vehicle 15 minutes before intravenously administered topotecan (1 mg/kg). Plasma levels of topotecan were determined at 1, 5, 15, 30, 60, 120, and 240 minutes. Results are the means ± standard deviation (n 3). d) Cumulative biliary excretion of topotecan. Bile was collected through a cannula in the gallbladder of mdr1a/1b(-/-) mice with a ligated common bile duct. Mice received an oral dose of GF120918 (50 mg/kg) or vehicle 15 minutes before topotecan (1 mg/kg) was administered intravenously. Levels of unchanged topotecan in bile were determined at 10, 20, 30, 40, 50, and 60 minutes. Results are the means ± standard deviation (n = 3).
|
|
Topotecan is a weak to moderate substrate for P-gp (24). Because the bioavailability of topotecan administered orally to vehicle-treated wild-type mice (41 ± 7 hours mg/L) is twofold lower than that in vehicle-treated P-gp-deficient mdr1a/1b(-/-) mice (96 ± 18 hours mg/L) (P<.001; compare lower curves in Fig. 3
, a and b), P-gp also appears to have a role in the bioavailability of topotecan. When wild-type mice, clinically the most relevant model, were treated with GF120918, the bioavailability of topotecan given orally increased ninefold (381 ± 41 versus 41 ± 7 hours mg/L; P<.001). This result indicates that inhibition of both Bcrp1 and P-gp by GF120918 has a strong effect on uptake of topotecan administered orally, although the resulting availability did not quite reach the level observed in GF120918-treated mdr1a/1b(-/-) mice (596 ± 62 hours mg/L).
We next determined how GF120918 given orally affected the levels of topotecan excreted in the small intestine. GF120918 was administered orally to mdr1a/1b(-/-) mice; 15 minutes later, [14C]topotecan was administered intravenously; then 15 and 60 minutes later, the amount of [14C]topotecan excreted into the small intestine was measured. Fifteen and 60 minutes after [14C]topotecan was administered to GF120918-treated animals, the percentage of total [14C]topotecan in the small intestinal lumen was about twofold and threefold lower, respectively, and the plasma levels were about 1.5-fold and 2.5-fold higher compared with vehicle-treated animals (Table 1
). These observations could reflect diminished excretion of topotecan into the small intestine and/or increased (re-)uptake from the small intestine, both caused by GF120918. To analyze this effect further, we separately determined the hepatobiliary, direct intestinal, and renal excretion of [14C]topotecan. For the measurement of hepatobiliary excretion, anesthetized mdr1a/1b(-/-) mice with a cannulated gallbladder were given GF120918 or vehicle orally 15 minutes before they were given [14C]topotecan intravenously, and the amount of topotecan excreted was determined over the next hour. Hepatobiliary excretion of unchanged topotecan was substantially decreased in GF120918-treated animals for the first 10 minutes after topotecan administration (5.5% ± 2.6%) compared with that of vehicle-treated animals (14.7 % ± 2.4%) (P = .011); however, after about 20 minutes, the excretion rate in both gradually became similar (Fig. 3
, d). This observation and the fact that biliary topotecan excretion was not completely blocked by GF120918 suggest that hepatic Bcrp1 was not completely blocked by GF120918 or that there are additional transporters for topotecan in the bile canalicular membrane. In contrast to the hepatobiliary excretion of topotecan, the effect of GF120918 treatment on direct intestinal (7.5% ± 2.5% with GF120918 and 11.6% ± 1.1% with vehicle) or renal (12.6% ± 7.9% with GF120918 and 18.0% ± 10.4% with vehicle) excretion of total radioactivity was not statistically significant. These data suggest that the GF120918-induced high bioavailability of topotecan administered orally results primarily from a combination of its increased intestinal (re-)uptake and decreased hepatobiliary excretion.
Pharmacologic Role of Bcrp1 in Placenta
P-gp has been shown to be functionally active in the pharmacologically important bloodbrain, bloodtestis, and maternalfetal barriers (10,20). The high expression of BCRP messenger RNA (mRNA) in human placenta and (to a lesser extent) in mouse placenta suggested to us that BCRP might also play a role in protecting fetuses against xenobiotics. So that we could test this hypothesis, pregnant mdr1a/1b(-/-) dams at gestation day 15.5 were administered GF120918 or vehicle orally 2 hours before intravenous administration of [14C]topotecan; 30 minutes after receiving [14C]topotecan, fetuses and maternal plasma were collected. We found that levels of [14C]topotecan were about 3.2-fold higher in fetuses of GF120918-treated dams, whereas at the same time maternal plasma levels were only about 1.6-fold increased (Table 1
). These results indicate that mouse Bcrp1 plays an important role in protecting the fetus from topotecan. Because BCRP mRNA expression is much higher in human placenta, the role of BCRP in humans could be even more pronounced. In contrast, for the bloodbrain and bloodtestis barriers, we found no indication that Bcrp1 has a role in limiting drug penetration, as determined by the distribution of intravenously administered [14C]topotecan or [3H]mitoxantrone in tissues of GF120918-treated and vehicle-treated mdr1a/1b (-/-) mice (data not shown).
 |
DISCUSSION
|
---|
Our data show that Bcrp1 mediates apically directed transport of its drug substrates and support the view that Bcrp1 is important in preventing intestinal (re-)uptake and in mediating hepatobiliary excretion of transported drugs. In these ways, Bcrp1 restricts the bioavailability of orally administered drugs. Moreover, it also protects fetuses through its presence in the maternalfetal barrier. Our data strongly suggest that Bcrp1 is present and functional in the apical membrane of the intestinal epithelium, in the bile canalicular membrane, and in the membrane of placental trophoblasts that is in contact with the maternal circulation.
The highest levels of bcrp1 mRNA were found in the kidney, suggesting that Bcrp1 might play an important pharmacologic role in the renal excretion of substrate drugs. Our experiments measuring this renal excretion gave highly variable results between individual mice and were essentially not influenced by GF120918 (12.6% ± 7.9% with GF120918 and 18.0% ± 10.4% with vehicle). Studies in patients also have found high variability in renal elimination of topotecan (mean = 40%; range = 26%80%) (25). A possible explanation for the high variability in renal excretion is that human and murine kidneys could have several transport mechanisms for topotecan that vary extensively among individuals.
Oral administration of drugs is highly preferred for its convenience and potential use on an outpatient basis. However, the therapeutic use of orally administered drugs is frequently limited by the poor and (consequently) highly variable drug bioavailability, factors that are largely determined by the extent to which the drugs are absorbed from the gut, metabolized, and excreted. The narrow therapeutic index of most anticancer drugs implies that this variability will frequently result in excessive toxicity or, conversely, in inadequate efficacy. For instance, for topotecan administered orally, the bioavailability in humans is moderate, with a high inter-patient variation (30% ± 7.7%) (26), and current chemotherapeutic schedules for topotecan are, therefore, mainly based on intravenous administration (27). Our findings suggest that, by combining topotecan administered orally with an effective BCRP (and P-gp) inhibitor, such as GF120918, the bioavailability of topotecan and thus its clinical usefulness might be dramatically improved. We should note that, based on these data, no conclusions can be made about whether the therapeutic index of topotecan (i.e., toxicity of topotecan for a tumor as opposed to its overall toxicity to the organism) is improved by GF120918. However, the ability to inhibit placental Bcrp1 with orally administered GF120918 suggests that a BCRP component of multidrug resistance in clinical tumors could also be blocked with GF120918 administered orally because the systemic exposure to GF120918 is apparently high enough.
Although we cannot exclude the possibility that other, as yet unidentified, GF120918-sensitive topotecan transporters are also contributing to the in vivo pharmacologic effects that we observed, the potential clinical application of GF120918 to improve the bioavailability of topotecan administered orally to patients should be pursued. In fact, we have started clinical trials to test whether it is feasible to increase the bioavailability of topotecan administered orally to patients by blocking BCRP with GF120918. If this procedure is successful in patients as well, it may prove to be applicable to other drugs transported by BCRP.
 |
NOTES
|
---|
Supported by grants NKI 97-1434 and NKI 97-1433 (to A. H. Schinkel) and NKI 99-2060 (to J. H. M. Schellens and A. H. Schinkel) from the Dutch Cancer Society.
We thank J. D. Allen, P. Borst, and O. van Tellingen for their suggestions with regard to the manuscript; Glaxo Wellcome (Research Triangle Park, NC) for providing GF120918; SmithKline Beecham Pharmaceuticals (King of Prussia, PA) for providing [14C]topotecan; and E. Nooteboom and A. S. Pfauth for their excellent technical assistance.
 |
REFERENCES
|
---|
1
Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;445:15262.
2
Gros P, Croop J, Housman D. Mammalian multidrug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell 1986;47:37180.[Medline]
3
Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258:16504.[Medline]
4
Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 1998;95:1566570.[Abstract/Free Full Text]
5
Ross DD, Yang W, Abruzzo LV, Dalton WS, Schneider E, Lage H, et al. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst 1999;91:42933.[Abstract/Free Full Text]
6
Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Cristensen B, et al. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res 1999;59:813.[Abstract/Free Full Text]
7
Allen JD, Brinkhuis RF, Wijnholds J, Schinkel AH. The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res 1999;59:423741.[Abstract/Free Full Text]
8
Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RC, Ruevekamp-Helmers MC, et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 1999;59:455963.[Abstract/Free Full Text]
9
de Bruin M, Miyake K, Litman T, Robey R, Bates SE. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett 1999;146:11726.[Medline]
10
Schinkel AH. The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol 1997;8:16170.[Medline]
11
Mayer U, Wagenaar E, Beijnen JH, Smit JW, Meijer DK, van Asperen J, et al. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr1a P-glycoprotein. Br J Pharmacol 1996;119:103844.[Abstract]
12
Herben VM, ten Bokkel Huinink WW, Dubbelman AC, Mandjes IA, Groot Y, van Gortel-van Zomeren DM, et al. Phase I and pharmacologic study of sequential intravenous topotecan and oral etoposide. Br J Cancer 1997;76:15008.[Medline]
13
Rosing H, van Zomeren DM, Doyle E, ten Bokkel WW, Schellens JH, Bult A, et al. Quantification of topotecan and its metabolite N-desmethyltopotecan in human plasma, urine and faeces by high-performance liquid chromatographic methods. J Chromatogr B Biomed Sci Appl 1999;727:191203.[Medline]
14
Jonker JW, Wagenaar E, van Deemter L, Gottschlich R, Bender HM, Dasenbrock J, et al. Role of blood-brain barrier P-glycoprotein in limiting brain accumulation and sedative side-effects of asimadoline, a peripherally acting analgaesic drug. Br J Pharmacol 1999;127:4350.[Abstract/Free Full Text]
15
Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994;77:491502.[Medline]
16
Michiels F, van der Kammen RA, Janssen L, Nolan G, Collard JG. Expression of Rho GTPases using retroviral vectors. Methods Enzymol 2000;325:295302.[Medline]
17
Kinsella TM, Nolan GP. Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Hum Gene Ther 1996;7:140513.[Medline]
18
Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 1995;96:1698705.[Medline]
19
Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A 1997;94:20315.[Abstract/Free Full Text]
20
Meerum Terwogt JM, Beijnen JH, ten Bokkel Huinink WW, Rosing H, Schellens JH. Co-administration of cyclosporin enables oral therapy with paclitaxel [letter] [published erratum appears in Lancet 1998;352:824]. Lancet 1998;352:285.
21
Smit JW, Huisman MT, van Tellingen O, Wiltshire HR, Schinkel AH. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J Clin Invest 1999;104:14417.[Abstract/Free Full Text]
22
Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 1998;58:53379.[Abstract]
23
Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 1993;53:4595602.[Abstract]
24
Chen AY, Yu C, Potmesil M, Wall ME, Wani MC, Liu LF. Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res 1991;51:603944.[Abstract]
25
Herben VM, ten Bokkel Huinink WW, Beijnen JH. Clinical pharmacokinetics of topotecan. Clin Pharmacokinet 1996;31:85102.[Medline]
26
Schellens JH, Creemers GJ, Beijnen JH, Rosing H, de Boer-Dennert M, McDonald M, et al. Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. Br J Cancer 1996;73:126871.[Medline]
27
van Warmerdam LJ, Verweij J, Schellens JH, Rosing H, Davies BE, de Boer-Dennert M, et al. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. Cancer Chemother Pharmacol 1995;35:23745.[Medline]
Manuscript received March 7, 2000;
revised July 31, 2000;
accepted August 7, 2000.
This article has been cited by other articles in HighWire Press-hosted journals:
-
Huang, L., Wang, Y., Grimm, S.
(2006). ATP-DEPENDENT TRANSPORT OF ROSUVASTATIN IN MEMBRANE VESICLES EXPRESSING BREAST CANCER RESISTANCE PROTEIN. Drug Metab. Dispos.
34: 738-742
[Abstract]
[Full Text]
-
Wang, H., Zhou, L., Gupta, A., Vethanayagam, R. R., Zhang, Y., Unadkat, J. D., Mao, Q.
(2006). Regulation of BCRP/ABCG2 expression by progesterone and 17beta-estradiol in human placental BeWo cells. Am. J. Physiol.
290: E798-E807
[Abstract]
[Full Text]
-
Evseenko, D. A., Paxton, J. W., Keelan, J. A.
(2006). ABC drug transporter expression and functional activity in trophoblast-like cell lines and differentiating primary trophoblast. Am. J. Physiol.
290: R1357-R1365
[Abstract]
[Full Text]
-
Nezasa, K.-i., Tian, X., Zamek-Gliszczynski, M. J., Patel, N. J., Raub, T. J., Brouwer, K. L. R.
(2006). ALTERED HEPATOBILIARY DISPOSITION OF 5 (AND 6)-CARBOXY-2',7'-DICHLOROFLUORESCEIN IN Abcg2 (Bcrp1) AND Abcc2 (Mrp2) KNOCKOUT MICE. Drug Metab. Dispos.
34: 718-723
[Abstract]
[Full Text]
-
Merino, G., Alvarez, A. I., Pulido, M. M., Molina, A. J., Schinkel, A. H., Prieto, J. G.
(2006). BREAST CANCER RESISTANCE PROTEIN (BCRP/ABCG2) TRANSPORTS FLUOROQUINOLONE ANTIBIOTICS AND AFFECTS THEIR ORAL AVAILABILITY, PHARMACOKINETICS, AND MILK SECRETION. Drug Metab. Dispos.
34: 690-695
[Abstract]
[Full Text]
-
zu Schwabedissen, H. E. M., Grube, M., Dreisbach, A., Jedlitschky, G., Meissner, K., Linnemann, K., Fusch, C., Ritter, C. A., Volker, U., Kroemer, H. K.
(2006). EPIDERMAL GROWTH FACTOR-MEDIATED ACTIVATION OF THE MAP KINASE CASCADE RESULTS IN ALTERED EXPRESSION AND FUNCTION OF ABCG2 (BCRP). Drug Metab. Dispos.
34: 524-533
[Abstract]
[Full Text]
-
Henrich, C. J., Bokesch, H. R., Dean, M., Bates, S. E., Robey, R. W., Goncharova, E. I., Wilson, J. A., McMahon, J. B.
(2006). A High-Throughput Cell-Based Assay for Inhibitors of ABCG2 Activity. J Biomol Screen
11: 176-183
[Abstract]
-
Herwaarden, A. E.v., Wagenaar, E., Karnekamp, B., Merino, G., Jonker, J. W., Schinkel, A. H.
(2006). Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk. Carcinogenesis
27: 123-130
[Abstract]
[Full Text]
-
Rudek, M. A., Zhao, M., Smith, N. F., Robey, R. W., He, P., Hallur, G., Khan, S., Hidalgo, M., Jimeno, A., Colevas, A. D., Messersmith, W. A., Wolff, A. C., Baker, S. D.
(2005). In vitro and In vivo Clinical Pharmacology of Dimethyl Benzoylphenylurea, a Novel Oral Tubulin-Interactive Agent. Clin Cancer Res
11: 8503-8511
[Abstract]
[Full Text]
-
Dilda, P. J., Don, A. S., Tanabe, K. M., Higgins, V. J., Allen, J. D., Dawes, I. W., Hogg, P. J.
(2005). Mechanism of Selectivity of an Angiogenesis Inhibitor From Screening a Genome-Wide Set of Saccharomyces cerevisiae Deletion Strains. J Natl Cancer Inst
97: 1539-1547
[Abstract]
[Full Text]
-
Kalabis, G. M., Kostaki, A., Andrews, M. H., Petropoulos, S., Gibb, W., Matthews, S. G.
(2005). Multidrug Resistance Phosphoglycoprotein (ABCB1) in the Mouse Placenta: Fetal Protection. Biol Reprod
73: 591-597
[Abstract]
[Full Text]
-
Mathias, A. A., Hitti, J., Unadkat, J. D.
(2005). P-glycoprotein and breast cancer resistance protein expression in human placentae of various gestational ages. Am. J. Physiol.
289: R963-R969
[Abstract]
[Full Text]
-
Hirano, M., Maeda, K., Matsushima, S., Nozaki, Y., Kusuhara, H., Sugiyama, Y.
(2005). Involvement of BCRP (ABCG2) in the Biliary Excretion of Pitavastatin. Mol Pharmacol
68: 800-807
[Abstract]
[Full Text]
-
Mirchandani, D., Hochster, H., Hamilton, A., Liebes, L., Yee, H., Curtin, J. P., Lee, S., Sorich, J., Dellenbaugh, C., Muggia, F. M.
(2005). Phase I Study of Combined Pegylated Liposomal Doxorubicin with Protracted Daily Topotecan for Ovarian Cancer. Clin Cancer Res
11: 5912-5919
[Abstract]
[Full Text]
-
Zhou, X.-f., Yang, X., Wang, Q., Coburn, R. A., Morris, M. E.
(2005). EFFECTS OF DIHYDROPYRIDINES AND PYRIDINES ON MULTIDRUG RESISTANCE MEDIATED BY BREAST CANCER RESISTANCE PROTEIN: IN VITRO AND IN VIVO STUDIES. Drug Metab. Dispos.
33: 1220-1228
[Abstract]
[Full Text]
-
Meyer zu Schwabedissen, H. E., Jedlitschky, G., Gratz, M., Haenisch, S., Linnemann, K., Fusch, C., Cascorbi, I., Kroemer, H. K.
(2005). VARIABLE EXPRESSION OF MRP2 (ABCC2) IN HUMAN PLACENTA: INFLUENCE OF GESTATIONAL AGE AND CELLULAR DIFFERENTIATION. Drug Metab. Dispos.
33: 896-904
[Abstract]
[Full Text]
-
Vethanayagam, R. R., Wang, H., Gupta, A., Zhang, Y., Lewis, F., Unadkat, J. D., Mao, Q.
(2005). FUNCTIONAL ANALYSIS OF THE HUMAN VARIANTS OF BREAST CANCER RESISTANCE PROTEIN: I206L, N590Y, AND D620N. Drug Metab. Dispos.
33: 697-705
[Abstract]
[Full Text]
-
Sesink, A. L. A., Arts, I. C. W., de Boer, V. C. J., Breedveld, P., Schellens, J. H. M., Hollman, P. C. H., Russel, F. G. M.
(2005). Breast Cancer Resistance Protein (Bcrp1/Abcg2) Limits Net Intestinal Uptake of Quercetin in Rats by Facilitating Apical Efflux of Glucuronides. Mol Pharmacol
67: 1999-2006
[Abstract]
[Full Text]
-
Merino, G., van Herwaarden, A. E., Wagenaar, E., Jonker, J. W., Schinkel, A. H.
(2005). Sex-Dependent Expression and Activity of the ATP-Binding Cassette Transporter Breast Cancer Resistance Protein (BCRP/ABCG2) in Liver. Mol Pharmacol
67: 1765-1771
[Abstract]
[Full Text]
-
Merino, G., Jonker, J. W., Wagenaar, E., van Herwaarden, A. E., Schinkel, A. H.
(2005). The Breast Cancer Resistance Protein (BCRP/ABCG2) Affects Pharmacokinetics, Hepatobiliary Excretion, and Milk Secretion of the Antibiotic Nitrofurantoin. Mol Pharmacol
67: 1758-1764
[Abstract]
[Full Text]
-
Xia, C. Q., Liu, N., Yang, D., Miwa, G., Gan, L.-S.
(2005). EXPRESSION, LOCALIZATION, AND FUNCTIONAL CHARACTERISTICS OF BREAST CANCER RESISTANCE PROTEIN IN CACO-2 CELLS. Drug Metab. Dispos.
33: 637-643
[Abstract]
[Full Text]
-
Merino, G., Jonker, J. W., Wagenaar, E., Pulido, M. M., Molina, A. J., Alvarez, A. I., Schinkel, A. H.
(2005). TRANSPORT OF ANTHELMINTIC BENZIMIDAZOLE DRUGS BY BREAST CANCER RESISTANCE PROTEIN (BCRP/ABCG2). Drug Metab. Dispos.
33: 614-618
[Abstract]
[Full Text]
-
Breedveld, P., Pluim, D., Cipriani, G., Wielinga, P., van Tellingen, O., Schinkel, A. H., Schellens, J. H.M.
(2005). The Effect of Bcrp1 (Abcg2) on the In vivo Pharmacokinetics and Brain Penetration of Imatinib Mesylate (Gleevec): Implications for the Use of Breast Cancer Resistance Protein and P-Glycoprotein Inhibitors to Enable the Brain Penetration of Imatinib in Patients. Cancer Res
65: 2577-2582
[Abstract]
[Full Text]
-
Kolwankar, D., Glover, D. D., Ware, J. A., Tracy, T. S.
(2005). EXPRESSION AND FUNCTION OF ABCB1 AND ABCG2 IN HUMAN PLACENTAL TISSUE. Drug Metab. Dispos.
33: 524-529
[Abstract]
[Full Text]
-
Zhou, S., Zong, Y., Ney, P. A., Nair, G., Stewart, C. F., Sorrentino, B. P.
(2005). Increased expression of the Abcg2 transporter during erythroid maturation plays a role in decreasing cellular protoporphyrin IX levels. Blood
105: 2571-2576
[Abstract]
[Full Text]
-
Adachi, Y., Suzuki, H., Schinkel, A. H., Sugiyama, Y.
(2005). Role of Breast Cancer Resistance Protein (Bcrp1/Abcg2) in the Extrusion of Glucuronide and Sulfate Conjugates from Enterocytes to Intestinal Lumen. Mol Pharmacol
67: 923-928
[Abstract]
[Full Text]
-
Ejendal, K. F. K., Hrycyna, C. A.
(2005). Differential Sensitivities of the Human ATP-Binding Cassette Transporters ABCG2 and P-Glycoprotein to Cyclosporin A. Mol Pharmacol
67: 902-911
[Abstract]
[Full Text]
-
Zhang, S., Wang, X., Sagawa, K., Morris, M. E.
(2005). FLAVONOIDS CHRYSIN AND BENZOFLAVONE, POTENT BREAST CANCER RESISTANCE PROTEIN INHIBITORS, HAVE NO SIGNIFICANT EFFECT ON TOPOTECAN PHARMACOKINETICS IN RATS OR MDR1A/1B (-/-) MICE. Drug Metab. Dispos.
33: 341-348
[Abstract]
[Full Text]
-
Kobayashi, D., Ieiri, I., Hirota, T., Takane, H., Maegawa, S., Kigawa, J., Suzuki, H., Nanba, E., Oshimura, M., Terakawa, N., Otsubo, K., Mine, K., Sugiyama, Y.
(2005). FUNCTIONAL ASSESSMENT OF ABCG2 (BCRP) GENE POLYMORPHISMS TO PROTEIN EXPRESSION IN HUMAN PLACENTA. Drug Metab. Dispos.
33: 94-101
[Abstract]
[Full Text]
-
Pavek, P., Merino, G., Wagenaar, E., Bolscher, E., Novotna, M., Jonker, J. W., Schinkel, A. H.
(2005). Human Breast Cancer Resistance Protein: Interactions with Steroid Drugs, Hormones, the Dietary Carcinogen 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and Transport of Cimetidine. J. Pharmacol. Exp. Ther.
312: 144-152
[Abstract]
[Full Text]
-
Lee, Y.-J., Kusuhara, H., Jonker, J. W., Schinkel, A. H., Sugiyama, Y.
(2005). Investigation of Efflux Transport of Dehydroepiandrosterone Sulfate and Mitoxantrone at the Mouse Blood-Brain Barrier: A Minor Role of Breast Cancer Resistance Protein. J. Pharmacol. Exp. Ther.
312: 44-52
[Abstract]
[Full Text]
-
Stewart, C. F., Leggas, M., Schuetz, J. D., Panetta, J. C., Cheshire, P. J., Peterson, J., Daw, N., Jenkins, J. J. III, Gilbertson, R., Germain, G. S., Harwood, F. C., Houghton, P. J.
(2004). Gefitinib Enhances the Antitumor Activity and Oral Bioavailability of Irinotecan in Mice. Cancer Res
64: 7491-7499
[Abstract]
[Full Text]
-
de Jong, F. A., Marsh, S., Mathijssen, R. H. J., King, C., Verweij, J., Sparreboom, A., McLeod, H. L.
(2004). ABCG2 Pharmacogenetics: Ethnic Differences in Allele Frequency and Assessment of Influence on Irinotecan Disposition. Clin Cancer Res
10: 5889-5894
[Abstract]
[Full Text]
-
Mizuno, N., Suzuki, M., Kusuhara, H., Suzuki, H., Takeuchi, K., Niwa, T., Jonker, J. W., Sugiyama, Y.
(2004). IMPAIRED RENAL EXCRETION OF 6-HYDROXY-5,7-DIMETHYL-2-METHYLAMINO-4-(3-PYRIDYLMETHYL) BENZOTHIAZOLE (E3040) SULFATE IN BREAST CANCER RESISTANCE PROTEIN (BCRP1/ABCG2) KNOCKOUT MICE. Drug Metab. Dispos.
32: 898-901
[Abstract]
[Full Text]
-
Breedveld, P., Zelcer, N., Pluim, D., Sonmezer, O., Tibben, M. M., Beijnen, J. H., Schinkel, A. H., van Tellingen, O., Borst, P., Schellens, J. H. M.
(2004). Mechanism of the Pharmacokinetic Interaction between Methotrexate and Benzimidazoles: Potential Role for Breast Cancer Resistance Protein in Clinical Drug-Drug Interactions. Cancer Res
64: 5804-5811
[Abstract]
[Full Text]
-
Bates, S. E., Medina-Perez, W. Y., Kohlhagen, G., Antony, S., Nadjem, T., Robey, R. W., Pommier, Y.
(2004). ABCG2 Mediates Differential Resistance to SN-38 (7-Ethyl-10-hydroxycamptothecin) and Homocamptothecins. J. Pharmacol. Exp. Ther.
310: 836-842
[Abstract]
[Full Text]
-
Ward, K. W., Azzarano, L. M.
(2004). Preclinical Pharmacokinetic Properties of the P-Glycoprotein Inhibitor GF120918A (HCl salt of GF120918, 9,10-Dihydro-5-methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]phenyl]-4-acridine-carboxamide) in the Mouse, Rat, Dog, and Monkey. J. Pharmacol. Exp. Ther.
310: 703-709
[Abstract]
[Full Text]
-
Gupta, A., Zhang, Y., Unadkat, J. D., Mao, Q.
(2004). HIV Protease Inhibitors Are Inhibitors but Not Substrates of the Human Breast Cancer Resistance Protein (BCRP/ABCG2). J. Pharmacol. Exp. Ther.
310: 334-341
[Abstract]
[Full Text]
-
Polli, J. W., Baughman, T. M., Humphreys, J. E., Jordan, K. H., Mote, A. L., Webster, L. O., Barnaby, R. J., Vitulli, G., Bertolotti, L., Read, K. D., Serabjit-Singh, C. J.
(2004). THE SYSTEMIC EXPOSURE OF AN N-METHYL-D-ASPARTATE RECEPTOR ANTAGONIST IS LIMITED IN MICE BY THE P-GLYCOPROTEIN AND BREAST CANCER RESISTANCE PROTEIN EFFLUX TRANSPORTERS. Drug Metab. Dispos.
32: 722-726
[Abstract]
[Full Text]
-
Ozvegy-Laczka, C., Heged""s, T., Varady, G., Ujhelly, O., Schuetz, J. D., Varadi, A., Keri, G., Orfi, L., Nemet, K., Sarkadi, B.
(2004). High-Affinity Interaction of Tyrosine Kinase Inhibitors with the ABCG2 Multidrug Transporter. Mol Pharmacol
65: 1485-1495
[Abstract]
[Full Text]
-
Zhang, S., Yang, X., Morris, M. E.
(2004). Flavonoids Are Inhibitors of Breast Cancer Resistance Protein (ABCG2)-Mediated Transport. Mol Pharmacol
65: 1208-1216
[Abstract]
[Full Text]
-
Sankatsing, S. U. C., Beijnen, J. H., Schinkel, A. H., Lange, J. M. A., Prins, J. M.
(2004). P Glycoprotein in Human Immunodeficiency Virus Type 1 Infection and Therapy. Antimicrob. Agents Chemother.
48: 1073-1081
[Full Text]
-
Ee, P. L. R., Kamalakaran, S., Tonetti, D., He, X., Ross, D. D., Beck, W. T.
(2004). Identification of a Novel Estrogen Response Element in the Breast Cancer Resistance Protein (ABCG2) Gene. Cancer Res
64: 1247-1251
[Abstract]
[Full Text]
-
Nakanishi, T., Doyle, L. A., Hassel, B., Wei, Y., Bauer, K. S., Wu, S., Pumplin, D. W., Fang, H.-B., Ross, D. D.
(2003). Functional Characterization of Human Breast Cancer Resistance Protein (BCRP, ABCG2) Expressed in the Oocytes of Xenopus laevis. Mol Pharmacol
64: 1452-1462
[Abstract]
[Full Text]
-
Dietrich, C G, Geier, A, Oude Elferink, R P J
(2003). ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut
52: 1788-1795
[Full Text]
-
Pang, K. S.
(2003). MODELING OF INTESTINAL DRUG ABSORPTION: ROLES OF TRANSPORTERS AND METABOLIC ENZYMES (FOR THE GILLETTE REVIEW SERIES). Drug Metab. Dispos.
31: 1507-1519
[Full Text]
-
van Herwaarden, A. E., Jonker, J. W., Wagenaar, E., Brinkhuis, R. F., Schellens, J. H. M., Beijnen, J. H., Schinkel, A. H.
(2003). The Breast Cancer Resistance Protein (Bcrp1/Abcg2) Restricts Exposure to the Dietary Carcinogen 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Cancer Res
63: 6447-6452
[Abstract]
[Full Text]
-
Imai, Y., Asada, S., Tsukahara, S., Ishikawa, E., Tsuruo, T., Sugimoto, Y.
(2003). Breast Cancer Resistance Protein Exports Sulfated Estrogens but Not Free Estrogens. Mol Pharmacol
64: 610-618
[Abstract]
[Full Text]
-
Mizuno, N., Niwa, T., Yotsumoto, Y., Sugiyama, Y.
(2003). Impact of Drug Transporter Studies on Drug Discovery and Development. Pharmacological Reviews
55: 425-461
[Abstract]
[Full Text]
-
Chen, Z.-S., Robey, R. W., Belinsky, M. G., Shchaveleva, I., Ren, X.-Q., Sugimoto, Y., Ross, D. D., Bates, S. E., Kruh, G. D.
(2003). Transport of Methotrexate, Methotrexate Polyglutamates, and 17{beta}-Estradiol 17-({beta}-D-glucuronide) by ABCG2: Effects of Acquired Mutations at R482 on Methotrexate Transport. Cancer Res
63: 4048-4054
[Abstract]
[Full Text]
-
Shimano, K., Satake, M., Okaya, A., Kitanaka, J., Kitanaka, N., Takemura, M., Sakagami, M., Terada, N., Tsujimura, T.
(2003). Hepatic Oval Cells Have the Side Population Phenotype Defined by Expression of ATP-Binding Cassette Transporter ABCG2/BCRP1. Am J Pathol
163: 3-9
[Abstract]
[Full Text]
-
Suzuki, M., Suzuki, H., Sugimoto, Y., Sugiyama, Y.
(2003). ABCG2 Transports Sulfated Conjugates of Steroids and Xenobiotics. J. Biol. Chem.
278: 22644-22649
[Abstract]
[Full Text]
-
Elferink, R O.
(2003). Cholestasis. Gut
52: ii42-48
[Abstract]
[Full Text]
-
Allen, J. D., van Dort, S. C., Buitelaar, M., van Tellingen, O., Schinkel, A. H.
(2003). Mouse Breast Cancer Resistance Protein (Bcrp1/Abcg2) Mediates Etoposide Resistance and Transport, but Etoposide Oral Availability Is Limited Primarily by P-glycoprotein. Cancer Res
63: 1339-1344
[Abstract]
[Full Text]
-
Kruijtzer, C.M.F., Beijnen, J.H., Schellens, J.H.M.
(2002). Improvement of Oral Drug Treatment by Temporary Inhibition of Drug Transporters and/or Cytochrome P450 in the Gastrointestinal Tract and Liver: An Overview. Oncologist
7: 516-530
[Abstract]
[Full Text]
-
Jonker, J. W., Buitelaar, M., Wagenaar, E., van der Valk, M. A., Scheffer, G. L., Scheper, R. J., Plosch, T., Kuipers, F., Elferink, R. P. J. O., Rosing, H., Beijnen, J. H., Schinkel, A. H.
(2002). The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc. Natl. Acad. Sci. U. S. A.
99: 15649-15654
[Abstract]
[Full Text]
-
Stephens, R. H., Tanianis-Hughes, J., Higgs, N. B., Humphrey, M., Warhurst, G.
(2002). Region-Dependent Modulation of Intestinal Permeability by Drug Efflux Transporters: In Vitro Studies in mdr1a(-/-) Mouse Intestine. J. Pharmacol. Exp. Ther.
303: 1095-1101
[Abstract]
[Full Text]
-
Zhou, S., Morris, J. J., Barnes, Y., Lan, L., Schuetz, J. D., Sorrentino, B. P.
(2002). Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Proc. Natl. Acad. Sci. U. S. A.
99: 12339-12344
[Abstract]
[Full Text]
-
Hudes, G.
(2002). Boosting Bioavailability of Topotecan: What Do We Gain?. J Clin Oncol
20: 2918-2919
[Full Text]
-
Allen, J. D., Schinkel, A. H.
(2002). Multidrug Resistance and Pharmacological Protection Mediated by the Breast Cancer Resistance Protein (BCRP/ABCG2). Mol Cancer Ther
1: 427-434
[Full Text]
-
Allen, J. D., van Loevezijn, A., Lakhai, J. M., van der Valk, M., van Tellingen, O., Reid, G., Schellens, J. H. M., Koomen, G.-J., Schinkel, A. H.
(2002). Potent and Specific Inhibition of the Breast Cancer Resistance Protein Multidrug Transporter in Vitro and in Mouse Intestine by a Novel Analogue of Fumitremorgin C. Mol Cancer Ther
1: 417-425
[Abstract]
[Full Text]
-
Audus, K. L., Soares, M. J., Hunt, J. S.
(2002). Characteristics of the Fetal/Maternal Interface with Potential Usefulness in the Development of Future Immunological and Pharmacological Strategies. J. Pharmacol. Exp. Ther.
301: 402-409
[Abstract]
[Full Text]
-
Allen, J. D., Jackson, S. C., Schinkel, A. H.
(2002). A Mutation Hot Spot in the Bcrp1 (Abcg2) Multidrug Transporter in Mouse Cell Lines Selected for Doxorubicin Resistance. Cancer Res
62: 2294-2299
[Abstract]
[Full Text]
-
Faneyte, I. F., Kristel, P. M. P., Maliepaard, M., Scheffer, G. L., Scheper, R. J., Schellens, J. H. M., van de Vijver, M. J.
(2002). Expression of the Breast Cancer Resistance Protein in Breast Cancer. Clin Cancer Res
8: 1068-1074
[Abstract]
[Full Text]
-
Lebel, M.
(2002). Increased frequency of DNA deletions in pink-eyed unstable mice carrying a mutation in the Werner syndrome gene homologue. Carcinogenesis
23: 213-216
[Abstract]
[Full Text]
-
Taipalensuu, J., Tornblom, H., Lindberg, G., Einarsson, C., Sjoqvist, F., Melhus, H., Garberg, P., Sjostrom, B., Lundgren, B., Artursson, P.
(2001). Correlation of Gene Expression of Ten Drug Efflux Proteins of the ATP-Binding Cassette Transporter Family in Normal Human Jejunum and in Human Intestinal Epithelial Caco-2 Cell Monolayers. J. Pharmacol. Exp. Ther.
299: 164-170
[Abstract]
[Full Text]
-
Honjo, Y., Hrycyna, C. A., Yan, Q.-W., Medina-Perez, W. Y., Robey, R. W., van de Laar, A., Litman, T., Dean, M., Bates, S. E.
(2001). Acquired Mutations in the MXR/BCRP/ABCP Gene Alter Substrate Specificity in MXR/BCRP/ABCP-overexpressing Cells. Cancer Res
61: 6635-6639
[Abstract]
[Full Text]
-
Maliepaard, M., Scheffer, G. L., Faneyte, I. F., van Gastelen, M. A., Pijnenborg, A. C. L. M., Schinkel, A. H., van de Vijver, M. J., Scheper, R. J., Schellens, J. H. M.
(2001). Subcellular Localization and Distribution of the Breast Cancer Resistance Protein Transporter in Normal Human Tissues. Cancer Res
61: 3458-3464
[Abstract]
[Full Text]
-
Egorin, M. J.
(2000). Adenosine Triphosphate-Binding Cassette Proteins and Bioavailability: "We Can Pump You Up (or Out)". J Natl Cancer Inst
92: 1628-1629
[Full Text]
-
Kruijtzer, C. M.F., Beijnen, J. H., Rosing, H., ten Bokkel Huinink, W. W., Schot, M., Jewell, R. C., Paul, E. M., Schellens, J. H.M.
(2002). Increased Oral Bioavailability of Topotecan in Combination With the Breast Cancer Resistance Protein and P-Glycoprotein Inhibitor GF120918. J Clin Oncol
20: 2943-2950
[Abstract]
[Full Text]
 |
|